Read More

Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment In Ongoing Phase II Study Of BMF-219 In Adults With Type 2 Diabetes In Poster Presentation At WCIRDC

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetesAt Week 26, 22 weeks after the last dose of BMF-219, participants in the 100

BMEA

Read More

Biomea Fusion To Present Long-Term Follow-Up Data From Ongoing Phase II Study Of BMF-219 In Adults With Type 2 Diabetes And Results From Ex-Vivo Human Islet Experiments At The World Congress Insulin Resistance, Diabetes & Cardiovascular Disease

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes In a poster presentation on Thursday, Dec. 7th at 6:30pm and an oral

BMEA